| Literature DB >> 34054142 |
Abstract
Throughout the history, natural products always give new paths to develop new drugs. As with many other diseases, natural compounds can be helpful in the treatment of COVID-19. SARS-CoV-2 main protease enzyme has an important role in viral replication and transcription. Therefore, inhibiting this enzyme may be helpful in the treatment of COVID-19. In this study, it is aimed to investigate eight natural compounds which have recently entered the literature, computationally for their potential use against SARS-CoV-2. For this purpose, first, density functional theory (DFT) calculations were performed on the investigated compounds, and energy minimizations, geometry optimizations, vibrational analyses, molecular electrostatic potential map calculations were carried out. After DFT calculations, geometry optimized structures were subjected to molecular docking calculations with the use of SARS-CoV-2 main protease (pdb id: 5r80) and top-scoring ligand-receptor complexes were obtained. In the next part of the study, molecular dynamics (MD) simulations were performed on the top-scoring ligand-receptor complexes to investigate the stability of the ligand-receptor complexes and the interactions between ligands and receptor in more detail. Additionally, in this part of the study, binding free energies are calculated with the use of molecular mechanics with Poisson-Boltzmann surface area (MM-PBSA) method. Results showed that, all ligand-receptor complexes remain stable during the MD simulations and most of the investigated compounds but especially two of them showed considerably high binding affinity to SARS-CoV-2 main protease. Finally, in the study, ADME (adsorption, desorption, metabolism, excretion) predictions and drug-likeness analyses were performed on the investigated compounds.Entities:
Keywords: COVID-19; DFT; Drug-likeness analysis; Molecular docking; Molecular dynamics simulation; SARS-CoV-2 main protease
Year: 2021 PMID: 34054142 PMCID: PMC8140653 DOI: 10.1016/j.molstruc.2021.130733
Source DB: PubMed Journal: J Mol Struct ISSN: 0022-2860 Impact factor: 3.196
Fig. 1Chemical structures of the investigated compounds.
Fig. 2Optimized geometric structures of the compounds 1-8.
Fig. 3MEP maps of the compounds 1-8.
AutoDock Vina binding scores of the investigated compounds.
| Compound | AutoDock Vina Score |
|---|---|
| 1 | -8.6 |
| 2 | -7.5 |
| 3 | -7.5 |
| 4 | -7.7 |
| 5 | -6.2 |
| 6 | -6.6 |
| 7 | -7.5 |
| 8 | -7.6 |
| Remdesivir | -7.9 |
| Lopinavir | -8.2 |
| Favipiravir | -5.1 |
| Hydroxychloroquine | -6.3 |
Fig. 4Binding positions and ligand-receptor interactions at the end of 30 ns MD simulations.
Fig. 52D representations of ligand-receptor interactions at the end of 30 ns MD simulations.
Fig. 6Interactions between reference drugs and SARS-CoV-2 main protease at the end of 30 ns MD simulation.
Fig. 7RMSD of SARS-CoV-2 main protease compared to its initial position.
Fig. 8RMSD of ligand compared to SARS-CoV-2 main protease.
Fig. 9Changes in radius of gyration of SARS-CoV-2 main protease during the MD simulations.
Fig. 10RMSDs of reference drugs compared to the position of SARS-CoV-2 main protease.
Fig. 11RMSDs and RGs of enzyme obtained for the complexes of reference drugs.
Fig. 12Average binding free energies obtained from MM-PBSA calculations (Hyd: Hydroxychloroquine, Lop: Lopinavir, Rem: Remdesivir).
Results of ADME analyses of the investigated compounds.
| Compound | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Fav | Lop | Rem | Hyd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physicochemical Properties | ||||||||||||
| Number of H-Bond Acceptors | 5 | 5 | 5 | 6 | 4 | 5 | 7 | 4 | 4 | 5 | 12 | 3 |
| Number of H-Bond Donors | 2 | 2 | 2 | 1 | 3 | 4 | 6 | 3 | 2 | 4 | 4 | 2 |
| Molecular Weight (g/mol) | 338.4 | 354.4 | 300.3 | 314.3 | 266.3 | 284.4 | 372.4 | 284.3 | 157.1 | 628.8 | 602.5 | 335.8 |
| Number of heavy atoms | 25 | 26 | 22 | 23 | 19 | 20 | 27 | 21 | 11 | 46 | 42 | 23 |
| Number of aromatic heavy atoms | 12 | 12 | 12 | 12 | 0 | 0 | 12 | 14 | 6 | 18 | 15 | 10 |
| Fraction C sp3 | 0.25 | 0.29 | 0.29 | 0.24 | 0.67 | 0.80 | 0.38 | 0.18 | 0.00 | 0.43 | 0.48 | 0.50 |
| Number of rotatable bonds | 1 | 4 | 1 | 1 | 3 | 3 | 7 | 1 | 1 | 17 | 14 | 9 |
| Molar refractivity | 92.81 | 98.90 | 80.16 | 80.58 | 72.51 | 74.14 | 100.72 | 83.95 | 32.91 | 187.92 | 150.43 | 98.57 |
| TPSA (Å2) | 75.99 | 75.99 | 68.15 | 85.22 | 77.76 | 97.99 | 74.22 | 69.92 | 88.84 | 120.00 | 213.36 | 48.39 |
| Lipophilicity | ||||||||||||
| iLOGP | 3.02 | 2.91 | 2.64 | 2.32 | 1.75 | 1.55 | 3.29 | 2.41 | 0.39 | 4.22 | 3.40 | 3.58 |
| XLOGP3 | 3.47 | 3.89 | 3.28 | 2.37 | 0.27 | -0.96 | 2.63 | 4.06 | -0.56 | 5.92 | 1.91 | 3.58 |
| WLOGP | 2.82 | 3.26 | 2.88 | 2.52 | 0.96 | 0.01 | 3.19 | 3.74 | -0.57 | 3.57 | 2.21 | 3.59 |
| MLOGP | 1.55 | 1.78 | 1.96 | 1.06 | 0.80 | 0.07 | 1.31 | 2.35 | -1.30 | 2.93 | 0.18 | 2.35 |
| SILICOS-IT | 3.02 | 3.87 | 3.23 | 2.91 | 1.81 | 0.93 | 4.03 | 3.55 | 0.69 | 6.02 | -0.55 | 3.73 |
| Consensus logPo/w | 2.78 | 3.14 | 2.80 | 2.24 | 1.12 | 0.32 | 2.89 | 3.22 | -0.27 | 4.53 | 1.53 | 3.77 |
| Water Solubility | ||||||||||||
| ESOL | MS | MS | MS | S | VS | VS | S | MS | VS | PS | MS | S |
| ALI | MS | MS | MS | S | VS | VS | S | MS | VS | PS | PS | MS |
| SILICOS-IT | MS | MS | MS | MS | S | S | MS | MS | S | IS | MS | PS |
| Pharmacokinetics | ||||||||||||
| GI Absorption | High | High | High | High | High | High | High | High | High | High | Low | High |
| BBB Permeation | Yes | Yes | Yes | No | No | No | Yes | Yes | No | No | No | Yes |
| Skin permeation, logKp (cm/s) | -5.90 | -5.70 | -5.80 | -6.53 | -7.73 | -8.72 | -6.70 | -5.15 | -7.66 | -5.93 | -8.62 | -5.81 |
Fav: Favipiravir, Lop: Lopinavir, Rem: Remdesivir, Hyd: Hydroxychloroquine, TPSA: Topological Polar Surface Area, GI: Gastrointestinal, BBB: Blood Brain Barrier, IS: Insoluble, PS: Poorly soluble, MS: Moderately soluble, S: Soluble, VS: Very soluble.
Results of drug-likeness and medicinal chemistry analyses.
| Compound | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Fav | Lop | Rem | Hyd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug-likeness | ||||||||||||
| Lipinksi | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes |
| Ghose | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No | Yes |
| Veber | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Yes |
| Egan | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes |
| Muegge | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No | Yes |
| ABS | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.17 | 0.55 |
| Medicinal Chemistry | ||||||||||||
| PAINS (alerts) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brenk (alerts) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Leadlikeness | Yes | No (2) | Yes | Yes | Yes | Yes | No (1) | No (1) | No (1) | No (3) | No (2) | No (2) |
| SAS | 4.27 | 4.12 | 3.54 | 3.53 | 4.19 | 4.55 | 4.03 | 1.60 | 2.08 | 5.67 | 6.33 | 2.82 |
Fav: Favipiravir, Lop: Lopinavir, Rem: Remdesivir, Hyd: Hydroxychloroquine, ABS: Abbott Bioavailability Score, PAINS: Pan Assay Interference Structures, SAS: Synthetic Accessibility Score.